担忧和影响力的担忧ammatory Bowel Disease Patients Followed Prospectively over One Year
Table 6
Comparison of scores at V1 and V2 in patients reporting improvement or deterioration of IBD symptoms. Effect-size calculated with Cohen’sd.
V1
V2
Difference (95% CI)
Cohen’sd
value
Improvement of symptoms mean (SD)
F1 Impact of disease
22
45.4 (18.9)
26.6 (17.2)
18.7 (12.6–24.9)
1.04
<0.001
F2 Expectancy
22
49.1 (22.6)
31.2 (24.5)
17.9 (8.8–27.0)
0.75
0.002
F3 Treatment
22
48.4 (24.3)
23.1 (18.6)
25.4 (15.0–35.8)
1.16
0.049
F4亲密
22
32.5 (25.5)
18.7 (23.0)
13.8 (6.1–21.6)
0.56
<0.001
F5 Stigma
22
34.5 (23.1)
19.2 (17.9)
15.3 (6.4–24.2)
0.74
0.009
F6 Complications
22
33.9 (21.7)
29.8 (25.2)
4.0 (−7.9–16.0)
0.17
0.112
Sum score
22
41.3 (15.7)
24.2 (16.6)
17.1 (12.0–22.3)
1.05
<0.001
Deterioration of symptoms mean (SD)
F1 Impact of disease
19
27.8 (16.3)
42.3 (20.8)
14.5 (20.4–8.5)
−0.77
<0.001
F2 Expectancy
19
44.8 (27.0)
51.9 (24.8)
7.1 (13.9–.3)
−0.27
<0.001
F3 Treatment
19
32.5 (22.4)
44.0 (23.8)
11.6 (22.3–.9)
−0.49
0.017
F4亲密
19
25.0 (22.7)
35.6 (22.2)
10.5 (21.0–.1)
−0.47
0.018
F5 Stigma
19
20.1 (16.7)
33.9 (25.7)
13.8 (23.1–4.6)
−0.63
0.002
F6 Complications
19
29.5 (20.0)
61.7 (21.5)
32.2 (42.6–21.8)
−1.55
<0.001
Sum score
19
31.7 (17.6)
42.3 (19.3)
10.6 (16.7–4.5)
−0.57
<0.001
Abbreviations: F1–F6: rating form of IBD patient concerns, factors 1–6. V1: baseline, V2: 6-months followup.
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy.Sign up hereas a reviewer to help fast-track new submissions.
